Chronic Wound Diagnostics Company Emunamedica Announces Receipt Of U.S. Patent Allowance

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--Emunamedica LLC, a privately-held diagnostics company, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering its first-in-class quantitative chronic wound diagnostic device currently under late-stage development. The patent to be issued from this allowed application, titled "Methods of Optically Monitoring Wound Healing" is the first allowance and was filed in conjunction with applications currently being prosecuted in Europe and Asia.

The Emunamedica platform technology has been clinically-proven to differentiate between healing and non-healing wounds in diabetic foot ulcer patients. Data from the study found that within four weeks, the Emunamedica system could positively predict 82% of the time whether a wound was going to heal, independent of therapy chosen (sensitivity=0.9; specificity=0.86; p < 0.002). Furthermore, with such data in hand clinicians could have discontinued ineffective treatments after the four week analysis period potentially saving over $12,600 per patient, based on the treatment regimen of patients in this study. Details were published in the journal Wound Repair and Regeneration.

“We believe that this patent allowance is another significant milestone in our effort to provide quantitative diagnostic capabilities for the over 6 million chronic wound patients in the U.S. that have no diagnostic alternatives today,” said David Kolb, Emunamedica Co-Founder. “The ability to get patients off the wrong wound therapy faster and onto the right therapy sooner will be a win for all in the wound care continuum – for patients, better healing rates; for clinicians, better tools; and for payers, an opportunity to discontinue ineffective therapies much sooner thereby lowering the overall cost of care.”

Over the past two years Emunamedica has completed initial development of its technology, conducted a multi-center clinical study and received a Category III CPT reimbursement code (0286T) for the procedure used with its device. Current efforts are focused on completing commercial design work for scale manufacturing and optimal clinical usability. The company expects to launch the commercial version of its diagnostic device in late 2015.

About Emunamedica:

Emunamedica is a leading quantitative wound diagnostics company. Chronic wounds affect over 6 million people in the United States and cost health insurers nearly $10 billion annually, growing at about 8% annually. More information is available about the company at www.emunamedica.com.

Contacts

Emunamedica LLC
David Kolb, 305-482-3760
Chairman
ir@emunamedica.com

Help employers find you! Check out all the jobs and post your resume.

Back to news